SentrySciences Signs Collaboration Agreement with Coriolis Pharma
Summary
LONGMONT, Colo., May 7, 2024 /PRNewswire-PRWeb/ -- ParticleSentryAI software employs deep machine learning to analyze images of subvisible particles in biopharmaceutical products and provides actionable data and insight during formulation development, scale-up, manufacturing and technology transfer. ParticleSentryAI software leverages the morphological and textural features encoded in the images to assist in determining the causes of protein aggregation and delivers actionable data to limit their impact. Coriolis considers this collaboration agreement as an excellent opportunity to advance its efforts to integrate innovative digital formulation approaches and to complement its own particle analysis offering with an AI-based service. Our collaboration provides a local solution for European customers interested in understanding how ParticleSentryAI software can improve their aggregate control strategy. Dr. Tim Menzen, Chief Technology Officer at Coriolis agrees that "After the fingerprinting approach was presented in several scientific publications, including those we have published together with SentrySciences, I am excited that Coriolis is now able to use ParticleSentryAI software, and explore the added value of morphological embeddings in particle images together with our clients in the context of biopharmaceutical drug product development."